Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005944|
Recruitment Status : Unknown
Verified June 2007 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : March 24, 2004
Last Update Posted : April 26, 2011
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
PURPOSE: Randomized phase II trial to compare the effectiveness of second-look surgery with or without intraperitoneal infusions of mitomycin and fluorouracil in treating patients who have colorectal cancer that is recurrent to the peritoneum.
|Condition or disease||Intervention/treatment||Phase|
|Colorectal Cancer Metastatic Cancer Primary Peritoneal Cavity Cancer||Drug: chemotherapy Drug: fluorouracil Drug: leucovorin calcium Drug: mitomycin C Procedure: conventional surgery Procedure: laparoscopic surgery||Phase 2|
OBJECTIVES: I. Compare the effect of second look surgery with or without intraperitoneal mitomycin and fluorouracil on the 3 year survival rate of patients with colorectal cancer who are at high risk for peritoneal cavity cancer. II. Compare the quality of life of patients treated with these regimens. III. Compare the toxicity of these regimens in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to center, risk group, presence of symptoms (yes vs no), and isolated disease (yes vs no). After primary surgery, all patients receive 6 months of chemotherapy consisting of leucovorin calcium IV followed by fluorouracil IV over 10 minutes on days 1-5 every 4 weeks. Patients then undergo second look surgery or laparoscopy at 8-12 months. Second look surgery or laparoscopy may be performed earlier if markers increase progressively for unknown reasons or symptoms of peritoneal cancer occur. Patients with recurrent disease that can be resected are randomized to one of two treatment arms. Patients with no residual disease or with unresectable disease are followed for survival. Arm I: Patients undergo complete resection of all detectable lesions followed immediately by intraperitoneal (IP) mitomycin on day 0 and fluorouracil IP on days 1-4. Patients also receive systemic chemotherapy consisting of leucovorin calcium IV over 2 hours and fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Systemic chemotherapy repeats every 2 weeks for 6 months. Arm II: Patients undergo complete or partial resection and then receive systemic chemotherapy as in arm I. Quality of life is assessed at baseline and then every 4 months for 3 years. All patients (including nonrandomized patients) are followed every 4 months for 3 years.
PROJECTED ACCRUAL: A total of 152 patients (76 randomized) will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence|
|Study Start Date :||November 1999|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005944
|Liege, Belgium, B-4000|
|CHR de Besancon - Hopital Jean Minjoz|
|Besancon, France, 25030|
|Bordeaux, France, 33076|
|CHU Ambroise Pare|
|Boulogne Billancourt, France, F-92104|
|Centre Hospitalier Universitaire de Dijon|
|Dijon, France, 21033|
|Centre Hospitalier Regional de Lille|
|Lille, France, 59037|
|Centre Leon Berard|
|Lyon, France, 69373|
|Institut J. Paoli and I. Calmettes|
|Marseille, France, 13273|
|CHU de la Timone|
|Marseille, France, 13385|
|Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle|
|Montpellier, France, 34298|
|CRLCC Nantes - Atlantique|
|Nantes-Saint Herblain, France, 44805|
|CHR Hotel Dieu|
|Nantes, France, 44093|
|Hopital L'Archet - 2|
|Nice, France, F-06202|
|C.H.R. de Nimes - Hopital Caremeau|
|Nimes, France, 30000|
|CHR D'Orleans - Hopital de la Source|
|Orleans, France, 45067|
|Centre Hospitalier Universitaire|
|Reims, France, 51092|
|Centre Paul Strauss|
|Strasbourg, France, 67085|
|Institut Gustave Roussy|
|Villejuif, France, F-94805|
|Study Chair:||Dominique Elias, MD||Gustave Roussy, Cancer Campus, Grand Paris|